Fresenius SE & Co. KGaA has sold 7.8 million shares of its dialysis subsidiary Fresenius Medical Care AG (FMC) for approximately €300 million, cutting its stake from 27.8% to roughly 25%. The placement with institutional investors was announced after Thursday's market close on 20 August 2026.
Deal terms and rationale
The shares represent about 2.9% of FMC's share capital. Fresenius said the proceeds will be used for debt reduction and to fund targeted investments in its Kabi and Helios growth platforms. Chief executive Michael Sen described the transaction as creating "additional financial leeway to invest capital in our growth platforms."
The company expects a book gain in the low-to-mid double-digit million euro range, which will be recognised in the group's Q3 2026 results. A lock-up of up to 45 days applies to Fresenius's remaining FMC shares.
Strategic context
The sale continues a gradual unwinding of Fresenius's once-dominant position in the dialysis provider it spun out decades ago. The parent has been reshaping its portfolio around generic pharmaceuticals (Kabi) and hospital operations (Helios), both of which have shown stronger organic growth than the capital-intensive dialysis business.
FMC, headquartered in Bad Homburg, remains the world's largest dialysis services provider with around 125,000 employees. Its chief executive is Helen Giza. Fresenius retains a blocking minority at 25%, enough to influence major corporate actions but short of the control it exercised at higher ownership levels.
| Item | Detail |
|---|---|
| Shares sold | 7.8 million FMC shares |
| Value | Roughly €300 million |
| Share of FMC capital | Around 2.9% |
| Fresenius stake before | 27.8% |
| Fresenius stake after | About 25% |
| Use of proceeds | Debt reduction + growth platforms (Kabi, Helios) |
| Expected book gain | Low-to-mid double-digit million euros in Q3 2026 |
| Lock-up | Up to 45 days on remaining shares |
Source: Handelsblatt, 20 Aug 2026
What happens next
The market will watch whether Fresenius uses the balance-sheet flexibility for bolt-on acquisitions in Kabi's biosimilars pipeline or Helios's international hospital expansion. The 45-day lock-up limits further near-term sales, but the trajectory suggests the parent is comfortable moving toward a pure financial stake in FMC over time.
Fresenius reports Q3 2026 results in November, when the book gain will be quantified and management may update guidance for the growth platforms.
